Kobune et al. indicated that aberrant Hh pathway activation is a feature of some CD34+ myeloid leukemic cells, and Hh inhibitors may have a therapeutic role in the treatment of AML [27]. This evidence concerns the gene CD34 and acute myeloid leukemia.